The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Avacta have to come out and explain what exactly has gone on.
This is my gripe. They removed 1b and then re added it and just put it in the timeline as q4. Start dose expansion followed on by p2
The think shareholders are sick and tired of trying to decipher Avacta's change of strategy. Makes you wonder of they muddy the water on purpose. Complete mess.
In simplistic terms. Avacta still need to complete a phase 1b study (does expansion). Before P2 can begin. It's usual practice for a drug trial amd was their original plan.
According to the gant chart. Q424- expansion studies start LEADING in to Phase 2. You guys are expecting them to finish dose expansion studies in a quarter?
It's a UK listed company on the LSE AIM market going by their regulations. 40 day blackout. I don't buy
Bella, I will give you a sportsman's bet that P2 doesn't begin this year?
They still need to do the dose expansion phase.
Phase 2 will last 18 months?
This raise won't see Avacta through to keeping ava6000 in house. Far from it. Phase 2 s scheduled to begin h1 2025? This fund raise sees avacta through till end of 2025?
Obviously all of that could be subject to change. I take every update from Avacta with a bathful of salt
What exactly were you expecting to hear?
Two weekly study is in full swing and that data along with the 1a data will be used for the dose expa sion study starting this year (hopefully) leading onto phase 2 h1 2025
Since it's Friday for a bit of fun I've decided Avacta needs a rebrand and a new name.
The new name should be pivotX since most companies have a x these days and Avacta has a habit of pivoting.
Nysize. Majority of posters posting anything negative have been abused on this forum.
Mchurk the avacta die hards, Timster et Al are far far worse than any other.
They have constantly abused anyone who has questioned Avacta.
Touk, I wouldn't read too much into that
Next update it will be something completely different
Interesting that the CEO hasn't made himself available for interviews today.
Every other major event at Avacta in recent times he has done a Vox etc interview.
I'd be weary of Avacta listing on the Nasdaq.
They would spend most of their time fending off investor lawsuits.
Recently
Neil Bell, the Chief Therapeutics Development officer left
Fiona McLaughlin the Chief Scientific officer left.
Chris Coughlin is brought on as temp then assumes a new head of R& D role
The company promised a data rich presentation in December for phase 1a. It was anything but (thank god Chris Coughlin did the talking though).
Simon Bennett is brought in as a deal maker
This is sold to shareholders as a natural evolution as the company enters the "commercial phase". Really? Are Avacta really at the commercialization stage? AVA6000 hasnt started efficay studies yet.
Weeks later the company does a massively leaked fundraise at 50 PENCE
Whatever is going on, its very odd and long term shareholder are being punished right now.
No, watching. An interview with the AIM circus is the last thing Avacta should do.
'' In light of the strong demand received both from existing investors and potential new holders, the Board has decided to increase the size of the Placing from approximately £20 million to £25.7 million.''
So why didn't Avacta accept the extra funds during the last fundraiser which was circa twice the price? Hindsight is obviously a wonderful thing. But couple that with blowing funds on dx. The strategy seems well off.